• 1
    Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32:141156.
  • 2
    D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332354.
  • 3
    Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346:865868.
  • 4
    Bosch J, Abraldes JG, Groszmann RJ. Current management of portal hypertension. J Hepatol 2003; 38:S54S68.
  • 5
    Merigan TC, Plotkin GR, Davidson CS. Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices. N Engl J Med 1962; 266:134135.
  • 6
    Bosch J, Groszmann RJ, Garcia-Pagan JC, Teres J, Garcia-Tsao G, Navasa M, Mas A, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10:962968.
  • 7
    Bosch J, Lebrec D, Jenkins SA. Development of analogues: successes and failures. Scand J Gastroenterol Suppl 1998; 226:313.
  • 8
    D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19:475505.
  • 9
    Aurell CJ, Bengtsson B, Ekholm K, Kasprzykowska R, Nilsson A, Persson R, Bengstdsen P, et al. Development of vasopressor specific vasotocin analogues with prolonged effects. In: GiraltE, AndreuD, eds. Peptides. Leiden: Escom Science Publishers, 1990;671673.
  • 10
    Bernadich C, Bandi JC, Melin P, Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998; 27:351356.
  • 11
    Castaneda B, Debernardi-Venon W, Bandi JC, Andreu V, Perez-del-Pulgar S, Moitinho E, Pizcueta P, et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000; 31:581586.
  • 12
    Castaneda B, Morales J, Lionetti R, Moitinho E, Andreu V, Perez-del-Pulgar S, Pizcueta P, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33:821825.
  • 13
    Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, Rodes J. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988; 254:G322G328.
  • 14
    Fernandez M, Pizcueta P, Garcia-Pagan JC, Feu F, Cirera I, Bosch J, Rodes J. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993; 18:389393.
  • 15
    Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986; 90:12321240.
  • 16
    Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27:12071212.
  • 17
    Cardenas A, Gines P, Uriz J, Bessa X, Salmeron JM, Mas A, Ortega R, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34:671676.
  • 18
    McCormick PA, Jenkins SA, McIntyre N, Burroughs AK. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut 1995; 36:100103.
  • 19
    Bickell WH, Wall MJ Jr, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331:11051109.
  • 20
    Roberts I, Evans P, Bunn F, Kwan I, Crowhurst E. Is the normalisation of blood pressure in bleeding trauma patients harmful? Lancet 2001; 357:385387.